IMV (NYSE:IMV) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. The firm presently has a $4.25 price target on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 7.88% from the stock’s current price.

According to Zacks, “IMV Inc. is a clinical-stage immuno-oncology company. Its proprietary drug development platform provides a patented delivery formulation which enables controlled and prolonged exposure of antigens to the immune system. The company’s pipeline consists of DPX-Survivac, DPX-E7 and DPX-RSV which are in clinical stage. IMV Inc. is based in Halifax, Canada. “

Several other equities research analysts have also commented on the company. Raymond James set a $10.00 price target on IMV and gave the stock a “market perform” rating in a research note on Monday, May 13th. HC Wainwright set a $12.00 price target on IMV and gave the stock a “buy” rating in a research note on Friday, May 10th. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $8.75.

Shares of NYSE:IMV opened at $3.94 on Thursday. IMV has a 12 month low of $2.90 and a 12 month high of $7.21.

IMV (NYSE:IMV) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.13) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.06). The firm had revenue of $0.10 million during the quarter.

Hedge funds have recently bought and sold shares of the stock. Morgan Stanley lifted its stake in IMV by 565.3% in the 1st quarter. Morgan Stanley now owns 25,068 shares of the company’s stock valued at $101,000 after buying an additional 21,300 shares in the last quarter. Hartford Financial Management Inc. lifted its stake in IMV by 15.0% in the 4th quarter. Hartford Financial Management Inc. now owns 26,850 shares of the company’s stock valued at $139,000 after buying an additional 3,500 shares in the last quarter. Ironwood Investment Management LLC purchased a new stake in IMV in the 1st quarter valued at approximately $135,000. Bank of Montreal Can lifted its stake in IMV by 18.5% in the 1st quarter. Bank of Montreal Can now owns 75,661 shares of the company’s stock valued at $304,000 after buying an additional 11,807 shares in the last quarter. Finally, First Manhattan Co. lifted its stake in IMV by 75.7% in the 1st quarter. First Manhattan Co. now owns 154,518 shares of the company’s stock valued at $620,000 after buying an additional 66,550 shares in the last quarter.

IMV Company Profile

IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.

Read More: What is Call Option Volume?

Get a free copy of the Zacks research report on IMV (IMV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.